| pubmed-article:9637775 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9637775 | lifeskim:mentions | umls-concept:C0026018 | lld:lifeskim |
| pubmed-article:9637775 | lifeskim:mentions | umls-concept:C0012920 | lld:lifeskim |
| pubmed-article:9637775 | lifeskim:mentions | umls-concept:C0596446 | lld:lifeskim |
| pubmed-article:9637775 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:9637775 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9637775 | pubmed:dateCreated | 1998-7-14 | lld:pubmed |
| pubmed-article:9637775 | pubmed:abstractText | Topographical image measures have been used to characterize the subnuclear distribution of DNA topoisomerase I in human tumor cell lines. This topographical analysis allowed a mathematical description of staining patterns to be produced that did not depend on subjective grading. The redistribution of topoisomerase I in response to increasing concentrations of topotecan was then monitored by this method. The cell lines were stained for topoisomerase I by indirect immunofluorescence methods. Digital imaging microscopy and image analysis were used to extract the nucleus from each cell, and nine parameters describing the topography of the distribution of topoisomerase I within the nucleus were computed for each. Use of multivariate analysis of variance enabled this nine-parameter set to be reduced to a single canonical variable, representing 60-90% of the observed internuclear variance. Plotting the canonical variable vs drug concentration resulted in dose-response curves that could be fitted well by a simple Emax model. From these curve fits, EC50 and Emax values for drug-induced redistribution of topoisomerase I were determined. Our results indicate that neither the maximum extent of topoisomerase I redistribution (Emax) nor the EC50 for drug-induced redistribution correlated well with the growth inhibition produced by continuous exposure to topotecan in these cell lines. However, the EC50 determined for the 1-h high-concentration exposure did reflect the growth inhibition produced in cells exposed to the drug for 1 h. The methodology described may also be generally applied to any antigen of interest. | lld:pubmed |
| pubmed-article:9637775 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637775 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637775 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9637775 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637775 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9637775 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9637775 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9637775 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9637775 | pubmed:issn | 0014-4827 | lld:pubmed |
| pubmed-article:9637775 | pubmed:author | pubmed-author:HorowitzLL | lld:pubmed |
| pubmed-article:9637775 | pubmed:author | pubmed-author:DanksM KMK | lld:pubmed |
| pubmed-article:9637775 | pubmed:author | pubmed-author:BakerS DSD | lld:pubmed |
| pubmed-article:9637775 | pubmed:author | pubmed-author:WadkinsR MRM | lld:pubmed |
| pubmed-article:9637775 | pubmed:copyrightInfo | Copyright 1998 Academic Press. | lld:pubmed |
| pubmed-article:9637775 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9637775 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9637775 | pubmed:volume | 241 | lld:pubmed |
| pubmed-article:9637775 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9637775 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9637775 | pubmed:pagination | 332-9 | lld:pubmed |
| pubmed-article:9637775 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:meshHeading | pubmed-meshheading:9637775-... | lld:pubmed |
| pubmed-article:9637775 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9637775 | pubmed:articleTitle | Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy. | lld:pubmed |
| pubmed-article:9637775 | pubmed:affiliation | Cancer Therapy and Research Center, Institute for Drug Development, 8122 Datapoint, Suite 700, San Antonio, Texas, 78229-3264, USA. | lld:pubmed |
| pubmed-article:9637775 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9637775 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9637775 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9637775 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9637775 | lld:pubmed |
